InSphero

🎤 Catch Dr. Jan Lichtenberg’s Talk in Kyoto! 🇯🇵 At the MaxWell Biosystems Symposium Kyoto 2025, our CEO and Co-founder Dr. Jan Lichtenberg, will speak at 11:10 AM on August 5th. 🧪 Talk Title: Shaping the future of drug testing: Scalable 3D tissue models meet a human-centric regulatory era   He’ll explore how 3D tissue models like organoids and spheroids are transforming drug discovery and safety testing, fueled by recent FDA and NIH shifts toward human-based, non-animal methods. Don’t miss his insights and a case study on liver safety testing, showing how 3D platforms are being adopted across pharma for more predictive, scalable, and ethical research. Heading to Kyoto? Be sure to connect with Jan! 🔗 Link to our activities is in the comments below. Paul Edgard Clémençon, Bärbel Ulmer, Christine Schwenk, Katherine Czysz, Arumugham (Ragoo) Raghunathan, Sue Grepper, PhD, Arnab China, Ph.D., Marie Engelene Obien, Urs Frey, Rositsa Hadzhipetrova, Abhiyan Viplav, Ph.D., Tina Žel #3DCellModels #Organoids #DrugDiscovery #Neurotechnology #InVitroModels #Biotech #Kyoto2025 #MaxWellBiosystems #ScientificInnovation

🌏While in Japan, Dr. Jan Lichtenberg, our CEO and Co-Founder, will take part in Expo 2025 Osaka on Monday, August 4, as a panelist in the session “Interdisciplinary Swiss-Japan Collaborations.”   Jan will join a distinguished group of science and technology leaders, including: 🔹 Kaori Sugihara 🔹Kyoko Suzuki Marumo Suzuki, Science & Technology Office, Embassy of Switzerland in Tokyo 🔹 Urs Frey, CEO of MaxWell Biosystems   📅 Date: Monday, August 4, 2025 🕔 Time: 5:15 PM 📍 Venue: Swiss Pavilion, Expo 2025 Osaka   Jan’s participation highlights the importance of interdisciplinary, Swiss-Japanese collaboration in driving innovation across life sciences and emerging technologies.   We look forward to a dynamic exchange of ideas at the Swiss Pavilion! See you there! Paul Edgard Clémençon, Bärbel Ulmer, Christine Schwenk, Katherine Czysz, Arumugham (Ragoo) Raghunathan, Sue Grepper, PhD, Arnab China, Ph.D., Marie Engelene Obien, Rositsa Hadzhipetrova, Abhiyan Viplav, Ph.D., Tina Žel   #Expo2025 #SwissPavilion #SwitzerlandJapan #Innovation #FutureOfComputing #ScienceAndTechnology #Collaboration #LifeSciences #InSphero

🔬 Need a human-relevant liver model that’s easy to use and ready when you are? Our assay-ready 3D InSight™ Human Liver Microtissues are designed for seamless in-lab use, just order, plate, and start generating insights into: 🧪 Predictive toxicology 🧬 Disease modeling 💊 Metabolism studies … and more. With 📚 30+ publications and benchmark studies supporting their performance, these microtissues help you work faster, smarter, and more confidently across drug safety, efficacy, and translational research. 🔗 Learn more via the link in comments 📩 Or message us to discuss how they can fit into your workflow! Jan Lichtenberg Madhu Lal Nag, MBS PhD Bruno Filippi Francisco Verdeguer Frauke Greve Lisa Hoelting Abhiyan Viplav, Ph.D. Donna Busler Sintuja Gonzalez Arjanit Dacic Olivier Frey Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Arnab China, Ph.D. Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Katherine Czysz Rositsa Hadzhipetrova Tina Žel #LiverModel #3DCellCulture #AssayReady #InVitro #DrugDevelopment #Toxicology #HumanRelevant #DiseaseModeling #PharmaInnovation #BiomedicalResearch #Microtissues #TranslationalResearch

✈️ On our way to Japan✈️ Our CEO and Co-founder, Dr. Jan Lichtenberg, will be heading to Japan for the MaxWell Biosystems Symposium Kyoto 2025, taking place on August 5th. This one-day event brings together a global community of leading researchers and innovators to explore the cutting-edge of neuroscience and neuroengineering, from advanced 2D platforms to pioneering developments in 3D modeling. It's an exciting time for the field, and we’re proud to be part of the conversation shaping the future of brain science and technology. If you’ll be in Kyoto, connect with Jan, he would love to meet fellow scientists, collaborators, and industry partners passionate about pushing the boundaries of neurotech. 🔬🧠✨ 🔗 Link to our activities is in the comments below. Paul Edgard Clémençon, Bärbel Ulmer, Christine Schwenk, Katherine Czysz, Arumugham (Ragoo) Raghunathan, Sue Grepper, PhD, Arnab China, Ph.D., Marie Engelene Obien, Urs Frey, Rositsa Hadzhipetrova, Abhiyan Viplav, Ph.D., Tina Žel #Neurotechnology #NeuroscienceInnovation #Neuroengineering #3DCellModels #Biotech #MaxWellBiosystems #Kyoto2025 #ScientificCommunity #BrainResearch

Great publication from Hesperos Inc. on their efforts to provide translatable tools to assess the effect of a panel of antimalarial drugs, showing how working with advanced in-vitro models can improve drug development. Well done James J. Hickman, Ph.D. and team, as well as the Gates Foundation! Looking forward to explore how we can push this further through the collaboration between Hesperos Inc. and InSphero .

🙏 A big THANK YOU to all fellow researchers who applied for the #HUMAIN Award 2025 – our joint initiative with the Physicians Committee for Responsible Medicine! While a team of highly experienced 3D in vitro experts is busy 🔎 reviewing the submitted proposals, we ask you to keep an 👀 eye on your email and stay tuned for upcoming announcements! 📢 Lisa Hoelting Janine McCarthy Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Wolfgang Moritz Arnab China, Ph.D. Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Katherine Czysz Sue Grepper, PhD Francisco Verdeguer Bruno Filippi Burcak Yesildag Laure-Anne Ligeon Olivier Frey Dr. Henriette Schneider Abhiyan Viplav, Ph.D. Rositsa Hadzhipetrova Tina Žel    #award #partnership #3dcellculture #toxicology #drugdiscovery #grant #NAMs #nonanimalmethods

🧠 Advancing Immuno-Oncology with 3D Insight™ Spheroids 🧪   At InSphero, we're helping researchers unlock deeper insights into immune-oncology drug mechanisms with our 3D Insight™ immune-competent tumor spheroid models.   By co-culturing 3D human tumor spheroids with peripheral blood mononuclear cells (PBMCs), our platform enables you to study how immune cells interact with tumors in a more physiologically relevant environment.   With this model, you can: 🔬 Observe immune cell–mediated tumor killing 🧬 Assess T cell activation, cytokine release, and cytotoxicity 🧪 Track immune cell infiltration into tumor tissues 🛡️ Model immune checkpoint blockade (PD-1/PD-L1, CTLA-4 inhibition)   Whether you're validating IO targets or testing combination therapies, 3D Insight™ provides the translational relevance you need to move faster and smarter. Video description: In our 3D InSight™ Lung Adenocarcinoma model, GFP-expressing A549 microtissues were cocultured with red-labeled PBMCs pre-activated via CD3/CD28 stimulation. Live-cell imaging over 2 days has shown dynamic immune-tumor interactions: activated PBMCs rapidly moved toward the 3D tumor microtissue, resulting in visible tumor killing, as indicated by a progressive loss of GFP signal. 🔗 Learn more about how our immune-competent platforms support predictive, human-relevant immuno-oncology research.   Madhu Lal Nag, MBS PhD, Laure-Anne Ligeon, Irina Agarkova, Charlotte Veser, Michał Rudnik, Tabea Gamma, Zuzanna Kotkowska, PhD, Arnab China, Ph.D., Paul Edgard Clémençon, Sue Grepper, PhD, Arumugham (Ragoo) Raghunathan, Bärbel Ulmer, Christine Schwenk, Rositsa Hadzhipetrova, Abhiyan Viplav, Ph.D., Tina Žel #ImmunoOncology #3DCellCulture #InSphero #IOresearch #CancerResearch #ImmuneCompetentModels #OrgansOnChips #TCellActivation #CheckpointInhibition #DrugDiscovery #HumanRelevant

🚨 Tumor Models Summit Starts Tomorrow in Boston! 🚨 We’re counting down the hours to the 13th Tumor Models Summit, where experts in preclinical oncology come together to shape the future of cancer research. 🎯 Don't miss our poster presentation! Poster Title: Recapitulating Tumor Complexity In Vitro: A High-Throughput 3D Microtissue Platform for Oncology Drug Screening and Validation 📍 Presented by: Arumugham (Ragoo) Raghunathan, PhD Explore how our 3D tumor microtissue platform supports more predictive, human-relevant oncology research, without relying on animal models. We’ll be showcasing innovations in:  🔬 3D multicellular tumor spheroids and patient-derived primary tumor models  🧠 Immuno-oncology platforms that replicate the tumor microenvironment  🧪 Efficacy, mechanism of action and antibody-penetration 📈 Support drug development, biomarker discovery and more 🎟 Attending the summit? Connect with Ragoo or Madhu Lal Nag, MBS PhD, our Chief Scientific Officer, we’d love to chat! 👉 Additional details on our oncology and immunology platforms can be found in the comments. Let’s build the future of oncology drug discovery, together. Laure-Anne Ligeon, Irina Agarkova, Charlotte Veser, Michał Rudnik, Tabea Gamma, Zuzanna Kotkowska, PhD, Arnab China, Ph.D., Paul Edgard Clémençon, Sue Grepper, PhD, Bärbel Ulmer, Christine Schwenk, Rositsa Hadzhipetrova, Abhiyan Viplav, Ph.D., Tina Žel #TumorModelsSummit #InSphero #3DCellCulture #OncologyResearch #ImmunoOncology #OrgansOnChips #DrugDiscovery #HumanRelevant #NonAnimalResearch #Biotech

🔬 Still facing bottlenecks in your 3D #invitro model development? You are not alone... The good news is that there's a smarter way forward.   From sourcing the right cells to maintaining consistency and saving time, our assay-ready 3D InSight™ Human Liver #Microtissues take the pressure off your team and keep your data reliable. 💡 Whether you're screening compounds or verifying mechanisms, our ready-to-use #human #liver assay plates eliminate prep work and deliver reproducible results every time.   👉 Click through to explore the solutions to common bottlenecks in our latest overview.   Learn more via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Bruno Filippi Francisco Verdeguer Frauke Greve Lisa Hoelting Abhiyan Viplav, Ph.D. Donna Busler Sintuja Gonzalez Arjanit Dacic Olivier Frey Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Arnab China, Ph.D. Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Katherine Czysz Tina Žel Rositsa Hadzhipetrova #DrugDiscovery #Toxicology #LiverDisease #3DMicrotissues #AssayReady #InVitroModels #LiverToxicity #InSphero #TheModelofExcellence™  

🚨 Meet Us at the 13th Tumor Models Summit – Boston, July 22–23 🚨 Madhu Lal Nag, MBS PhD, Chief Scientific Officer and Arumugham (Ragoo) Raghunathan, PhD, Senior Director Business Development, will be attending the Tumor Models Summit in Boston next week! As part of our commitment to advancing human-relevant cancer research, we’re looking forward to connecting with peers and partners to discuss the future of preclinical oncology models. At InSphero, we’re transforming cancer drug discovery with: 🔬 3D multicellular tumor spheroids and patient-derived primary tumor models 🧠 Immuno-oncology platforms that replicate the tumor microenvironment 🧪 Efficacy, mechanism of action and antibody-penetration 📈 Support drug development, biomarker discovery and more If you're attending the summit, reach out to Ragoo or Madhu, we’d love to connect and explore how our platforms, including Akura™ Flow organ-on-chip and Assay-Ready 3D tumor microtissues, can help drive more predictive, non-animal research. 👉 Additional details on our oncology and immunology platforms can be found in the comments. Laure-Anne Ligeon, Irina Agarkova, Charlotte Veser, Michał Rudnik, Tabea Gamma, Zuzanna Kotkowska, PhD, Arnab China, Ph.D., Paul Edgard Clémençon, Sue Grepper, PhD, Bärbel Ulmer, Christine Schwenk, Rositsa Hadzhipetrova, Abhiyan Viplav, Ph.D., Tina Žel #TumorModelsSummit #CancerResearch #ImmunoOncology #3DCellCulture #OrganOnChip #HumanRelevantModels #InSphero #OncologyInnovation #TumorMicroenvironment #Boston2025